Haleon PLC ( (GB:HLN) ) has issued an update.
Haleon PLC announced the repurchase of 581,885 ordinary shares as part of its share buyback program, initially announced on March 28, 2025. This transaction is part of Haleon’s strategy to manage its share capital and enhance shareholder value, impacting the number of shares with voting rights, which now stands at 9,034,907,985.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a portfolio that includes Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. The company is known for its trusted brands such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum, which are built on innovation and deep human understanding.
YTD Price Performance: 3.31%
Average Trading Volume: 27,838,266
Technical Sentiment Signal: Sell
Current Market Cap: £35.23B
For a thorough assessment of HLN stock, go to TipRanks’ Stock Analysis page.